2
ISSUE
posterior segment • innovation • enlightenment
09 | 03 | 22
PIE M A G A ZINE ’ S D A ILY CONGR E S S NE W S ON T HE P O S T E RIOR S E GME N T
HIGHLIGHTS
04
Renowned ophthalmologists from around the region discussed the use of the anti-VEGF injection over the last ten years.
05
YOURS Ophthalmologica Award 2022 recipient Dr. Enrico Borelli shared the major highlights and discoveries in using retinal imaging in the study of intermediate AMD and biomarkers.
07
World renowned experts discussed the latest clinical insights on faricimab as a new treatment option for nAMD patients.
Published by
Matt Young
CEO & Publisher
Hannah Nguyen COO & CFO
Robert Anderson Media Director
Gloria D. Gamat Chief Editor
Brooke Herron Editor
International Business Development
Ruchi Mahajan Ranga Brandon Winkeler Writers
Hazlin Hassan Joanna Lee Matt Herman Maricel Salvador Graphic Designer
Media MICE Pte. Ltd.
6001 Beach Road, #09-09 Golden Mile Tower, Singapore 199589 Tel. Nos.: +65 8186 7677 Email: enquiry@mediamice.com www.mediaMICE.com
piemagazine.org
Do Androids Dream of Neovascular AMD? by Matt Herman
E
URETINA 2022 rolls on as experts gave an update on the state of the art for AI and nAMD in a Day 2 symposium.
The golden age of machine intelligence is upon us, and researchers are scrambling to keep up. Near-daily advances in chip technology, algorithm modeling and deep learning are opening doors by the day in ophthalmology, and especially in the treatment of neovascular agerelated macular degeneration (nAMD). The advent of optical coherence tomography (OCT) has already revolutionized wet AMD therapy, and more breakthroughs have ushered in the next generation of 3D imaging and quantitative analysis. In this mid-day session on Day 2 of the 22nd EURETINA Congress (EURETINA 2022) in Hamburg, Germany, some of the pioneers at the cutting edge of artificial intelligence (AI) and wet AMD gave an overview of what AI can do for clinicians now and in posterity.
Database biomarker mania The new age being ushered in by AI is all about the biomarkers, and a mountain of insights are already being gleaned with the help of massive repositories of data. Cont. on Page 3 >>